HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis

Published:2019-02-07 Issue:5 Volume:60 Page:1340-1342
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Innocenti Idanna¹,Morelli Francesca²³,Autore Francesco²³,Corbingi Andrea¹,Pasquale Raffaella⁴,Sorà Federica¹,Pompili Maurizio⁵,Laurenti Luca¹

Affiliation:

1. Institute of Hematology, Università Cattolica del Sacro Cuore, Roma, Italy;

2. Institute of Hematology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy;

3. Institute of Internal Medicine, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy;

4. Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico, Institute of Hematology, Milano, Italy;

5. Institute of Internal Medicine, Università Cattolica del Sacro Cuore, Roma, Italy

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2018.1523401

Reference10 articles.

1. Prevalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience

2. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5)

3. Is HBV prophylaxis required during CLL treatment with ibrutinib?

4. Feasibility and safety of therapy with ibrutinib after antiviral control of hepatitis B virus (HBV) reactivation in chronic lymphocytic leukemia patients

5. Hepatitis B reactivation in patients receiving targeted therapies

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of infections for patient treated with ibrutinib in clinical practice;Frontiers in Oncology;2024-09-10

2. Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents;Cancers;2024-05-24

3. HBV Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors (BTKIs): a Systematic Review and Meta-Analysis;Current Infectious Disease Reports;2024-01

4. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era;World Journal of Gastroenterology;2023-09-07

5. Low incidence of hepatitis B virus reactivation in patients with hematological malignancies receiving novel anticancer drugs: A report from a high epidemic area and literature review;Journal of Microbiology, Immunology and Infection;2023-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3